Medical Disclaimer: This article is for educational purposes only and does not constitute medical advice. BPC-157 and TB-500 are not FDA-approved drugs. Their use should only be considered under the supervision of a licensed healthcare provider with expertise in peptide therapy. Never self-prescribe or purchase from unverified sources.
If you spend any time in peptide therapy communities, you have almost certainly heard the phrase "Wolverine Protocol." It refers to the practice of stacking two healing peptides — BPC-157 and TB-500 — to create a comprehensive tissue-repair regimen. The nickname is a nod to the comic-book mutant's superhuman regeneration, and while real-world results are far more modest, the combination has become one of the most discussed peptide stacks in 2026. Interest spiked after the HHS reclassification announcement in February 2026 moved both peptides back toward legal availability through compounding pharmacies.
This guide explains what each peptide does, why practitioners combine them, what the evidence says, and how to access them safely and legally.
What Is BPC-157?
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide — a chain of 15 amino acids — derived from a protein naturally found in human gastric juice. It has been studied extensively in preclinical models for its ability to accelerate healing across the gastrointestinal tract, tendons, ligaments, muscles, and the nervous system. Key mechanisms include upregulation of growth factors (VEGF, EGF, FGF), promotion of angiogenesis, nitric oxide modulation, and broad anti-inflammatory activity. Notably, BPC-157 is stable in stomach acid, which opens the door to oral administration — unusual for a peptide. For a deep dive, see our complete BPC-157 guide.
What Is TB-500?
TB-500 is a synthetic fragment of Thymosin Beta-4, a naturally occurring 43-amino-acid protein involved in cell migration, proliferation, and differentiation. Thymosin Beta-4 regulates actin, a structural protein essential for cell movement and tissue remodeling. TB-500 is known for its systemic effects: once injected, it circulates throughout the body rather than staying localized at the injection site. Research — primarily in animal models — has demonstrated benefits for wound healing, muscle repair, reduction of scar tissue and fibrosis, and modulation of inflammatory pathways. It is particularly valued for post-surgical recovery and chronic soft-tissue injuries.
Why Stack BPC-157 and TB-500?
The rationale for combining these two peptides comes down to complementary coverage:
- Local vs. Systemic: BPC-157 exerts its strongest effects at or near the injection site, making it ideal for targeted healing of a specific tendon, joint, or gut issue. TB-500 circulates systemically, supporting repair processes body-wide.
- Different Repair Pathways: BPC-157 primarily drives angiogenesis and growth-factor upregulation. TB-500 primarily modulates actin and cell migration. Together, they activate a broader range of healing cascades than either peptide alone.
- Inflammation Control: Both peptides reduce inflammation, but through different mechanisms — BPC-157 via nitric oxide modulation and cytokine reduction, TB-500 via immune-cell modulation and fibrosis reduction.
The result, according to practitioners who prescribe this combination, is faster and more complete recovery from injuries, surgeries, and chronic inflammatory conditions. It is important to note that no randomized controlled human trials have studied the two peptides in combination. The evidence base consists of separate preclinical studies for each peptide, plus clinical observations from prescribing physicians.
BPC-157 vs TB-500: Head-to-Head Comparison
| Feature | BPC-157 | TB-500 | Combined Stack |
|---|---|---|---|
| Primary Mechanism | Angiogenesis, growth factor upregulation, gut protection | Actin regulation, cell migration, systemic anti-inflammatory | Combined local repair + systemic regeneration |
| Scope of Action | Localized (near injection site) | Systemic (whole body) | Comprehensive (local + systemic) |
| Best For | Gut healing, tendon/ligament injuries, joint pain | Wound healing, muscle recovery, post-surgical repair | Multi-system recovery, complex or chronic injuries |
| Route of Administration | Subcutaneous injection; oral for gut targets | Subcutaneous or intramuscular injection | Both administered subcutaneously |
| Typical Dose Range* | 250–500 mcg/day | 2–5 mg twice/week (loading); 2–5 mg/week (maintenance) | Both regimens combined; adjusted by provider |
| Onset of Effects | Days to 1–2 weeks | 1–2 weeks | Often faster due to complementary mechanisms |
*Dose ranges are for educational reference only and reflect protocols discussed in clinical literature. Your physician must determine the appropriate dose for your situation.
Common Dosing Protocols
The following protocols are commonly discussed in clinical settings. They are not prescriptive — your physician must determine the appropriate regimen based on your condition, body weight, and medical history.
- BPC-157: 250–500 mcg per day, injected subcutaneously as close to the injury site as practical. Cycles typically run 4–8 weeks. For gut-related conditions, some providers prescribe oral BPC-157 capsules.
- TB-500: A loading phase of 2–5 mg administered twice per week for 4–6 weeks, followed by a maintenance phase of 2–5 mg once per week. TB-500 is injected subcutaneously; the injection site does not need to be near the injury because TB-500 acts systemically.
- Stack Protocol: Both peptides are used concurrently according to their individual schedules. Some practitioners stagger start dates or adjust doses when combining. Total cycle length is typically 8–12 weeks.
Legal Status in 2026
The legal landscape for BPC-157 and TB-500 has shifted dramatically:
- Late 2023: Both peptides were placed in Category 2 by the FDA, effectively banning their use in compounding pharmacies. This forced patients who had been using them legally to either stop or seek alternatives.
- February 27, 2026: The Department of Health and Human Services announced that approximately 14 peptides — including BPC-157 and TB-500 — would return to Category 1, restoring their eligibility for compounding.
- April 2026 (current): The formal FDA publication implementing the reclassification is still pending. However, many 503A compounding pharmacies have resumed filling prescriptions based on the HHS announcement.
Key legal facts: Neither BPC-157 nor TB-500 is an FDA-approved drug. They are available as compounded medications with a valid physician prescription. They are not available over the counter or as dietary supplements. For the latest regulatory updates, see our 2026 FDA Peptide Reclassification Guide and the live FDA Peptide Tracker.
Side Effects & Safety
Both peptides are generally well-tolerated in clinical use. Reported side effects include:
- Injection site reactions: Redness, mild swelling, or itching at the injection site — the most common side effect and typically transient.
- Nausea or dizziness: Occasionally reported, usually mild and self-limiting.
- Allergic reactions: Rare, but possible with any injectable peptide. Discontinue use and contact your provider immediately if you experience hives, difficulty breathing, or swelling.
Long-term safety data in humans is limited for both peptides. This is one of the reasons physician oversight is essential — your provider can monitor for adverse effects and adjust your protocol accordingly. For a comprehensive safety overview, read our Peptide Side Effects & Safety Guide.
What Does the Stack Cost?
Through legitimate compounding pharmacies, the BPC-157 + TB-500 stack typically costs $200–$500 per month, depending on dosage, pharmacy, and geographic region. This generally includes the compounded peptides only — physician consultation fees, lab work, and supplies (syringes, alcohol swabs, bacteriostatic water) may be additional. Some telehealth peptide clinics bundle everything into a monthly subscription. For detailed pricing breakdowns, see our 2026 Peptide Therapy Cost Guide.
Warning: Gray Market Products
Do not purchase peptides labeled "for research use only" or from unregulated online vendors. These products are not manufactured under pharmaceutical-grade conditions. Independent testing of gray-market peptides has repeatedly found issues including:
- Incorrect dosages (under- or over-dosed)
- Bacterial contamination
- Heavy metal contamination
- Substitution with different compounds entirely
- No sterility testing
The only safe way to obtain BPC-157 and TB-500 is through a prescription from a licensed healthcare provider, filled by a state-licensed 503A or FDA-registered 503B compounding pharmacy. Always request a Certificate of Analysis (COA) from the pharmacy.
Finding a Qualified Provider
A qualified peptide therapy provider should be a licensed physician (MD, DO, NP, or PA) with experience in peptide protocols. They should require baseline lab work, provide informed consent about off-label use, and source peptides from a registered compounding pharmacy. For a curated list of vetted clinics — including telehealth options — see our Best Peptide Therapy Clinics Online (2026) guide.
The bottom line: The BPC-157 + TB-500 stack represents one of the most promising peptide combinations for tissue repair and recovery available in 2026. But "promising" is not the same as "proven" — and these are not over-the-counter supplements. Work with a qualified physician, use only pharmacy-grade products, and set realistic expectations. For more peptide research, protocols, and provider information, visit our Peptides Resource Center.